Due Diligence Milestones Sample Clauses

Due Diligence Milestones. Luitpold shall proceed diligently to bring Licensed Products into commercial use in the Field of Use for humans as quickly as is reasonably possible after the Approval Date. Luitpold shall be deemed to satisfy the foregoing obligation if Luitpold has made at least one sale of the Licensed Products to a Distributor or another third party solely for use in the Field of Use ("First Sale") within ** days after the Approval Date.

Due Diligence Milestones. Licensee shall proceed diligently with the development of Licensed Products. Licensee shall be deemed to satisfy the foregoing obligation if Licensee achieves the following milestones within the time frame indicated: (a) Within thirty (30) months from Effective Date, Licensee shall file an Investigational New Drug Application ("IND") or its equivalent for a Licensed Product; and (b) Within the later of forty-eight (48) months from the filing of an IND under Section 2.3(a) hereinabove or seventy-eight (78) months from the Effective Date, Licensee shall file a Biologics License Application ("BLA") or its equivalent for A Licensed Product. (c) Licensee agrees: (i) to exert all continuing reasonably diligent efforts to register one or more Licensed Products for commercial sale for administration in humans in the Field of Use throughout the Territory and; (ii) to promote and market the Licensed Product(s) in such areas with all continuing reasonable commercial efforts so that the sales thereof may be maximized.

Due Diligence Milestones. Licensee shall proceed diligently with the development of Licensed Products. Licensee shall be deemed to satisfy the foregoing obligation if Licensee achieves the following milestones within the time frame indicated: (a) Within eighteen (18) months from Effective Date, Licensee shall file an Investigational New Drug Application ("IND") or its equivalent for a Licensed Product; and (b) Within fifty four (54) months from the Effective Date, Licensee shall file a Biologics License Application ("BLA") or its equivalent for a Licensed Product. (c) Licensee agrees: (i) to exert all continuing reasonably diligent efforts to register one or more Licensed Products for commercial sale for administration in humans in the Field of Use throughout the Territory and; (ii) to promote and market the Licensed Product(s) in such areas with all continuing reasonable commercial efforts so that the sales thereof may be maximized.

Due Diligence Milestones. Licensee shall use commercially reasonable efforts to develop, manufacture, sublicense, market and sell Licensed Products in the Fields of Use in accordance with the milestones defined here.

Due Diligence Milestones. Company shall timely achieve the due diligence milestones set forth on Schedule B.

Due Diligence Milestones. Company shall report in writing to UMB no later than [**] days following the occurrence or satisfaction of each of the due diligence milestones set forth on Schedule B. Company shall make milestone payments due upon achievement of the items set forth in Section 5.3.

Due Diligence Milestones. Licensee and UMBC shall negotiate in good faith the achievement of any performance milestones. There are no milestone payments required.

Due Diligence Milestones. The Licensee shall use, or shall cause its Sublicensee(s) to use, commercially reasonable efforts to develop, manufacture, sublicense, market and sell one or more Licensed Products in the Fields of Use and the Territory in accordance with the milestones defined here. [***]

Due Diligence Milestones a. At its sole discretion, Xxxxx may invoke the following Due Diligence Milestones Reductions on Oncorus within [***] ([***]) days of the relevant milestone date: i. In the event that [***] does not take place within [***] ([***]) months of the Effective Date, Xxxxx may by providing written notice apply the following amendments to the Agreement: 1. A Due Diligence Milestones Reduction of [***]% ([***] percent) shall apply to all subsequent License Fees.

Due Diligence Milestones. Milestone Achievement Date 1. Adhering to its development plan, a current version of which is attached as Exhibit D Ongoing 2. First commercial sale of a Product in the US Within [...***...] of the date of EUA approval; and in no event later than [...***...]